Home

research

Lead the field

Work with precision at unrivaled speed to make informed decisions backed up by science. To meet the challenges of modern drug discovery, take advantage of BioSolveIT’s detailed and precise results — without compromise. We will address every step of your needs, from start to finish.
partners

Discover with confidence

Profit from our long-standing experience and collaboration history with Fortune 100 pharma companies and academia. Our secure software has been developed and backed by renowned partners - including BAYER, Roche, Merck, BASF, and others. BioSolveIT’s success record is cited in thousands of publications worldwide.
start right away

Start right away

BioSolveIT’s technology is fine-tuned for the needs of the pharma industry, academics, beginners, and veterans alike. Clean and compherensive user interface removes the need for a learning curve. Easy access fostered by intuitive operation will maximize the likelihood of your success. Simply download the multiplatform software and discover active molecules!
drug discovery evolution

Experience drug discovery

Evolve the way you approach drug design, with the most liberating breakthrough. The stimulating interface creates a dialog between you and your compound where you can see why something is considered good or bad. Clean visualization combined with scientific finesse mold into a fun-to-use drug design experience.

Current news

category
Software
Double Release — SeeSAR 11.1 and infiniSee 3.2
October 14, 2021 12:19
The BioSolveIT October updates are here and this time we are proud to announce a simultanious double release of both our platforms SeeSAR and infiniSee. SeeSAR 11.1 SeeSAR Hephaestus received a powerful update to support users in their drug discovery efforts. The covalent complex assessment received a visual update where...
Read on
category
Webinars
Application of Artificial Intelligence to Structural-Functional Biology and Drug Design
Thu, 21 Oct 2021, 16:00
Despite technological advances, the conventional process of drug discovery and development still shows limited therapeutic efficacy. To date, we only partially understand disease pathophysiology, we see an overall deficiency in developing therapeutics that target overlapping dysregulated pathways, and the choice of therapeutically irrelevant drug targets. A key difficulty lies in...
Read on
category
Software
Asinex Covalent Library with over 50k molecules now available for SeeSAR
September 20, 2021 19:21
Today’s update for the drug design dashboard SeeSAR features the ready-to-dock covalent library set by Asinex including over 50k possible drug candidates. Warheads of compounds have been translated into a ready-to-dock format for SeeSAR for convenient import and easy covalent docking access. The broad range of featured warheads allows you...
Read on